Coiled Therapeutics plc operates as a clinical stage oncology company, which focuses on developing precision oncology therapies. Its products include the AO-252 TACC3 inhibitor programme and the STAT-6 siRNA programme. The company also conducts clinical development activities, including Phase I clinical trials. Coiled Therapeutics plc was formerly known as Roquefort Therapeutics plc and changed its name to Coiled Therapeutics plc in March 2026. The company is based in London, United Kingdom.
